Overview

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

Status:
Terminated

Trial end date:
2017-06-09

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety, the antitumor activity and the pharmacokinetics of ASP8273 in EGFR tyrosine kinase inhibitor (EGFR-TKI)-naïve patients with non-small cell lung cancer (NSCLC) harboring EGFR activating mutations.

Phase:

Phase 2

Details

Lead Sponsor:

Astellas Pharma Inc

Treatments:

Mitogens
Naquotinib